Literature DB >> 18040255

Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa.

Marsha A Apushkin1, Gerald A Fishman, Sandeep Grover, Mark J Janowicz.   

Abstract

PURPOSE: To demonstrate the presence of a rebound effect with the use of acetazolamide for the treatment of cystoid macular edema (CME) in patients with retinitis pigmentosa (RP).
METHODS: Six patients with RP and cystic-appearing lesions in the macula demonstrated by fluorescein angiography and/or optical coherence tomography (OCT) were treated with an oral form of carbonic anhydrase inhibitor (acetazolamide [500 mg]) as a single daily dose.
RESULTS: All patients, treated with acetazolamide for a period of 3 weeks to 5 weeks, had initial improvement of macular edema demonstrated by OCT. However, extended use of acetazolamide, for at least 8 weeks to 12 weeks, resulted in recurrence (rebound) of CME in 3 of the 6 patients.
CONCLUSIONS: Results from our study suggest that rebound of CME with the continued use of acetazolamide observed by OCT may occur more frequently than previously appreciated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040255     DOI: 10.1097/IAE.0b013e31805f6b79

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  16 in total

1.  Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa.

Authors:  Gerald A Fishman; Marsha A Apushkin
Journal:  Br J Ophthalmol       Date:  2007-01-10       Impact factor: 4.638

2.  The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa.

Authors:  Yasuhiro Ikeda; Toshio Hisatomi; Noriko Yoshida; Shoji Notomi; Yusuke Murakami; Hiroshi Enaida; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-04       Impact factor: 3.117

3.  Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome.

Authors:  Mohamed A Genead; Gerald A Fishman
Journal:  Arch Ophthalmol       Date:  2010-09

4.  Intravitreal dexamethasone implant for recalcitrant cystoid macular edema secondary to retinitis pigmentosa: a pilot study.

Authors:  Aditya Sudhalkar; Laurent Kodjikian; Nishikant Borse
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-04       Impact factor: 3.117

Review 5.  [Pharmacological concepts to treat hereditary retinal degenerations].

Authors:  C M Poloschek; H Jägle
Journal:  Ophthalmologe       Date:  2012-02       Impact factor: 1.059

6.  The relationship of central foveal thickness to urinary iodine concentration in retinitis pigmentosa with or without cystoid macular edema.

Authors:  Michael A Sandberg; Elizabeth N Pearce; Shyana Harper; Carol Weigel-DiFranco; Lois Hart; Bernard Rosner; Eliot L Berson
Journal:  JAMA Ophthalmol       Date:  2014-10       Impact factor: 7.389

7.  Treatment of adult-onset acute macular retinoschisis in enhanced s-cone syndrome with oral acetazolamide.

Authors:  Alessandro Iannaccone; Kenneth H Fung; Mari E Eyestone; Edwin M Stone
Journal:  Am J Ophthalmol       Date:  2008-10-04       Impact factor: 5.258

8.  Topical dorzolamide treatment of macular cysts in the enhanced S-cone syndrome patient.

Authors:  Marta Kiszkielis; Wojciech Lubiński; Krzysztof Penkala
Journal:  Doc Ophthalmol       Date:  2013-01-06       Impact factor: 2.379

9.  Clinical and Rehabilitative Management of Retinitis Pigmentosa: Up-to-Date.

Authors:  Francesco Parmeggiani; Giovanni Sato; Katia De Nadai; Mario R Romano; Andrea Binotto; Ciro Costagliola
Journal:  Curr Genomics       Date:  2011-06       Impact factor: 2.236

10.  A rare case of type 3 usher syndrome with bilateral cystoid macular edema treated with topical dorzolamide.

Authors:  Athul Puthalath; Ramanuj Samanta; Neeraj Saraswat; Ajai Agrawal; Anupam Singh; Mahsa Jamil
Journal:  Taiwan J Ophthalmol       Date:  2020-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.